4'epidoxorubicin plus verapamil in anthracycline--refractory cancer patients.
Four patients refractory to doxorubicin (DX) and 9 patients refractory to 4'epidoxorubicin (4'EpiDX) were treated with verapamil (VRP) (120 mg every 6 h for 3 days) plus 4'EpiDX (80 mg/m2 i.v. bolus, together with the 6th VRP administration). Three patients had partial remissions lasting 3, 3.5 and 7 months, respectively. Toxicity grading did not exceed usual levels. The study demonstrates that VRP, when added at conventional doses to 4'EpiDX, can induce objective responses in some patients refractory to anthracyclines.
Divisione di Radioterapia e Oncologia, U.S.S.L. 28, Legnago, Italy.
R
R
Demicheli
A
A
Jirillo
G
G
Bonciarelli
F
F
Lonardi
M
M
Balli
A
A
Bandello
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004351:Drug Resistance; D015251:Epirubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014700:Verapamil / Q000008:administration & dosage
D015251:Epirubicin; D014700:Verapamil